Review supports Allo-HSCT for BCR-ABL(+) AML with TKI and chemotherapy
A New Hope for Rare Blood Cancer Patients
This case report and literature review addresses the treatment of BCR-ABL(+) acute myeloid leukemia. The authors synthesize existing evidenc…
Doctors helped a patient with rare BCR-ABL positive leukemia survive by combining drugs, chemotherapy, and a stem cell transplant.
Drug Response Profiling in pediatric ALL yields 68% objective responses and bridges to cellular therapies
Can a simple test find the right drug to save children with tough leukemia?
A prospective, multicenter Drug Response Profiling registry of 340 children with relapsed or refractory acute lymphoblastic leukemia in 17 E…
A simple test matching leukemia drugs to patient cells helped 68% of children respond to treatment and gave 28 of 42 patients a chance to su…
Comprehensive geriatric assessment modifies treatment plans and associates with survival in older adults with gastrointestinal malignancies
Does a pre-surgery check-up actually change treatment plans and help older adults with cancer live longer?
This retrospective cohort study evaluated 273 adults aged ≥65 years referred for preoperative comprehensive geriatric assessment (CGA) at a …
A pre-surgery health check changed treatment plans for 21% of older cancer patients and was linked to better survival.
CT radiomics and transcriptomics predict chemotherapy response in advanced laryngeal cancer
New Scan Predicts Chemo Success Before Treatment Starts
A retrospective cohort study of 161 advanced laryngeal cancer patients found that a Random Forest model combining CT radiomics, transcriptom…
A new scan using CT images can predict if chemotherapy will work for advanced laryngeal cancer before treatment begins, helping doctors avoi…
CLEC14A methylation marker detects HSIL and cervical cancer with 100% sensitivity and 95.3% specificity in a cohort of 431 participants.
Can a simple blood test spot dangerous cervical cell changes before they become cancer?
This cohort study of 431 participants evaluated the CLEC14A cg05057720 methylation marker for detecting high-grade squamous intraepithelial …
A new blood test marker detects every case of dangerous cervical cell changes while correctly identifying normal tissue in over 95% of cases…
Classification framework shows 79% to 98% performance for oral squamous cell carcinoma on histopathological images
AI Learns to Ignore Stains to Spot Mouth Cancer
A computer-aided classification study evaluated a framework combining staining-bias suppression and structured multiple-instance aggregation…
New AI technology learns to ignore stain colors, helping doctors spot mouth cancer more accurately even when lab dyes vary.
Plasma metabolomics panels show high discriminating power for lung, colorectal, and ovarian cancers
Blood Test Finds Unique Chemical Fingerprints for Three Major Cancers
This metabolomics biomarker discovery study analyzed plasma from 615 patients with lung, colorectal, or ovarian cancer and 95 non-cancerous …
A new blood test finds unique chemical fingerprints for lung, ovarian, and colorectal cancers with high accuracy before tumors are visible.
Camonsertib plus gemcitabine shows preliminary activity in advanced solid tumors with DDR alterations
New Drug Combo Helps Some Solid Tumors Grow Slower
This Phase Ib trial evaluated camonsertib plus gemcitabine in 76 patients with advanced solid tumors harboring DDR gene alterations. Tumor r…
This combination might offer a new hope for patients whose tumors have stopped responding to standard treatments.
Pirtobrutinib shows activity in relapsed and refractory marginal zone lymphoma patients in a Phase 1/2 trial.
Early trial shows pirtobrutinib helped some patients with relapsed marginal zone lymphoma.
This Phase 1/2 trial evaluated pirtobrutinib in 36 patients with relapsed and refractory marginal zone lymphoma. The investigator-assessed o…
A new drug helped more than half of patients with relapsed lymphoma shrink their tumors, offering hope for those who have run out of other t…
Phase 1 trial of oral ASTX727 plus talazoparib in previously treated triple-negative metastatic breast cancer patients.
New Drug Combo Stops Breast Cancer Growth
This Phase 1 study enrolled 34 evaluable patients with previously treated triple-negative, hormone-resistant, or HER2-negative metastatic br…
This new combination may help some patients keep their cancer stable for months when other options have run out.
Lirafugratinib sequencing with futibatinib shows feasibility in FGFR2-driven cancers based on early-phase trial data
Can a new cancer drug work better if you switch to another drug after it stops?
This Phase I/II preprint trial evaluated lirafugratinib in 30 patients with FGFR2-driven cancers, including intrahepatic cholangiocarcinoma.…
When a cancer drug stops working, switching to a different one might help because the two medicines attack the disease in slightly different…
Early study of CDP1 plus chemotherapy showed promising activity and manageable safety in advanced penile cancer.
New Drug Combo Shrinks Advanced Penile Cancer Tumors
This prospective phase 1 study evaluated the safety and antitumor activity of CDP1 monotherapy or in combination with standard chemotherapy …
A new drug combo shrinks advanced penile cancer tumors, offering fresh hope for patients with rare, hard-to-treat disease.